Anti-tumor immune response induced by dendritic cells transduced with truncated PSMA IRES 4-1BBL recombinant adenoviruses

Cancer Letters

Volumn 293, Issue 2, 2010, Pages 254-262

  Youlin, Kuang ^a   Xiaodong, Weng ^a   Xiuheng, Liu ^a   Hengchen, Zhu ^a   Zhiyuan, Chen ^a   Botao, Jiang ^a   Hui, Chen ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

4 1BBL; Cancer immunotherapy; Costimulatory molecule; Dendritic cells; Prostate cancer; Recombinant adenovirus

Indexed keywords

ADENOVIRUS VECTOR; B7 ANTIGEN; CD137 LIGAND; CD86 ANTIGEN; GAMMA INTERFERON; PROSTATE SPECIFIC MEMBRANE ANTIGEN; CANCER VACCINE; PROSTATE SPECIFIC ANTIGEN; RECOMBINANT VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EMBRYO; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERNAL RIBOSOME ENTRY SITE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; TUMOR MODEL; UPREGULATION; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT; ADENOVIRUS; ANIMAL; C57BL MOUSE; CYTOTOXICITY; FEMALE; GENETIC TRANSDUCTION; GENETICS; IMMUNOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

ADENOVIRIDAE; MURINAE; MUS;

4-1BB LIGAND; ADENOVIRIDAE; ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; FEMALE; MALE; MICE; MICE, INBRED C57BL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TRANSDUCTION, GENETIC; UP-REGULATION; VACCINES, SYNTHETIC;

EID: 77952466558     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.01.011     Document Type: Article

References (39)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., Thun M.J. Cancer Statistics. CA Cancer J. Clin. 2008, 58:71-96.
2. Eder I.E., Haag P., Bartsch G., Klocker H. Gene therapy strategies in prostate cancer. Curr. Gene Ther. 2005, 5:1-10.
3. Nencioni A., Grünebach F., Schmidt S.M., Müller M.R., Boy D., Patrone F., Ballestrero A., Brossart P. The use of dendritic cells in cancer immunotherapy. Crit. Rev. Oncol. Hematol. 2008, 65:191-199.
4. Sonpavde G., Spencer D.M., Slawin K.M. Vaccine therapy for prostate cancer. Urolog. Oncol.: Semin. Original Invest. 2007, 25:451-459.
5. Horoszewicz J.S., Leong S.S., Kawinski E., Karr J.P., Rosenthal H., Chu T.M., Mirand E.A., Murphy G.P. LNCaP model of human prostatic carcinoma. Cancer Res. 1983, 43:1809-1818.
6. Henry M.D., Wen S., Silva M.D., Chandra S., Milton M., Worland P.J. A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer. Cancer Res. 2004, 64:7995-8001.
7. Ma D., Hopf C.E., Malewicz A.D., Donovan G.P., Senter P.D., Goeckler W.F., Maddon P.J., Olson W.C. Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen. Clin. Cancer Res. 2006, 12:2591-2596.
8. Bühler P., Wolf P., Gierschner D., Schaber I., Katzenwadel A., Schultze-Seemann W., Wetterauer U., Tacke M., Swamy M., Schamel W.W., Elsässer-Beile U. A bispecific diabody directed against prostate-specific membrane antigen, CD3 induces T-cell mediated lysis of prostate cancer cells. Cancer Immunol. Immunother. 2008, 57:43-52.
9. Oh S.T., Kim C.H., Park M.Y., Won E.H., Sohn H.J., Cho H.I., Kang W.K., Hong Y.K., Kim T.G. Dendritic cells transduced with recombinant adenoviruses induce more efficient anti-tumor immunity than dendritic cells pulsed with peptide. Vaccine 2006, 24:2860-2868.
10. Schumacher L., Ribas A., Dissette V.B., McBride W.H., Mukherji B., Economou J.S., Butterfield L.H. Human dendritic cell maturation by adenovirus transduction enhances tumor antigen-specific T-cell responses. J. Immunother. 2004, 27:191-200.
11. Tan P.H., Beutelspacher S.C., Xue S.A., Wang Y.H., Mitchell P., McAlister J.C., Larkin D.F., McClure M.O., Stauss H.J., Ritter M.A., Lombardi G., George A.J. Modulation of human dendritic-cell function following transduction with viral vectors: implications for gene therapy. Blood 2005, 105:3824-3832.
12. Watts T.H. Tnf/Tnfr family members in costimulation of T cell responses. Annu Rev. Immunol. 2005, 23:23-68.
13. Lynch D.H. The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer. Immunol. Rev. 2008, 222:277-286.
14. Lu Z.Y., Condomines M., Tarte K., Nadal L., Delteil M.C., Rossi J.F., Ferrand C., Klein B. B7-1 and 4-1BB ligand expression on a myeloma cell line makes it possible to expand autologous tumor-specific cytotoxic T cells in vitro. Exp. Hematol. 2007, 35:443-453.
15. Lee H.W., Park S.J., Choi B.K., Kim H.H., Nam K.O., Kwon B.S. 4-1BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xL and Bfl-1. J. Immunol. 2002, 169:4882-4888.
16. Croft M. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity?. Nat. Rev. Immunol. 2003, 3:609-620.
17. Kudo-Saito C., Hodge J.W., Kwak H., Kim-Schulze S., Schlom J., Kaufman H.L. 4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines. Vaccine 2006, 24:4975-4986.
18. Xiao H., Huang B., Yuan Y., Li D., Han L.F., Liu Y., Gong W., Wu F.H., Zhang G.M., Feng Z.H. Soluble PD-1 facilitates 4-1BBL-triggered antitumor immunity against murine H22 hepatocarcinoma in vivo. Clin. Cancer Res. 2007, 13:1823-1830.
19. Hellstrom K.E., Hellstrom I. Therapeutic vaccination with tumor cells that engage CD137. J. Mol. Med. 2003, 81:71-86.
20. Zhang H., Knutson K.L., Hellstrom K.E., Disis M.L., Hellstrom I. Antitumor efficacy of CD137 ligation is maximized by the use of a CD137 single-chain Fv-expressing whole-cell tumor vaccine compared with CD137-specific monoclonal antibody infusion. Mol. Cancer Ther. 2006, 5:149-155.
21. Cuadros C., Dominguez A.L., Lollini P.L., Croft M., Mittler R.S., Borgström P., Lustgarten J. Vaccination with dendritic cells pulsed with apoptotic tumors in combination with anti-OX40 and anti-4-1BB monoclonal antibodies induces T cell-mediated protective immunity in Her-2/neu transgenic mice. Int. J. Cancer 2005, 116:934-943.
22. Nagaraj S., Pisarev V., Kinarsky L., Sherman S., Muro-Cacho C., Altieri D.C., Gabrilovich D.I. Dendritic cell-based full-length surviving vaccine in treatment of experimental tumors. J. Immunother. 2007, 30:169-179.
23. Wu C., Liu F., Zhou X., Cheng Z., Yang X., Xiao H., Chen Q., Cai K. Effect of protein kinase C on proliferation and apoptosis of T lymphocytes in idiopathic thrombocytopenic purpura children. Cell Mol. Immunol. 2005, 2:197-203.
24. Nencioni A., Brossart P. Cellular immunotherapy with dendritic cells in cancer: current status. Stem Cells 2004, 22:501-513.
25. Waeckerle-Men Y., Uetz-von Allmen E., Fopp M., Von Moos R., Böhme C., Schmid H.P., Ackermann D., Cerny T., Ludewig B., Groettrup M., Gillessen S. Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma. Cancer Immunol. Immunother. 2006, 55:1524-1533.
26. Heiser A., Dahm P., Yancey D.R., Maurice M.A., Boczkowski D., Nair S.K., Gilboa E., Vieweg J. Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro. J. Immunol. 2000, 164:5508-5514.
27. Salucci V., Lena A.M., Ciliberto G., Scarselli E., La Monica N. Adenovirus transduction and culture conditions affect the immunogenicity of murine dendritic cells. Scand J. Immunol. 2005, 62:206-217.
28. + cytotoxic T-cell activation and antitumor immunity. Cancer Gene Ther. 2002, 9:202-208.
29. Wiethe C., Dittmar K., Doan T., Lindenmaier W., Tindle R. Provision of 4-1BB ligand enhances effector and memory CTL responses generated by immunization with dendritic cells expressing a human tumor-associated antigen. J. Immunol. 2003, 170:2912-2922.
30. DeBenedette M.A., Shahinian A., Mak T.W., Watts T.H. Costimulation of CD28 T lymphocytes by 4-IBBL ligand. J. Immunol. 1997, 158:551-559.
31. Cannons J.L., Lau P., Ghumman B., DeBenedette M.A., Yagita H., Okumura K., Watts T.H. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy. J. Immunol. 2001, 167:1313-1324.
32. Maus M.V., Thomas A.K., Leonard D.G., Allman D., Addya K., Schlienger K., Riley J.L., June C.H. Ex vivo expansion of polyclonal, antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat. Biotechnol. 2002, 20:143-148.
33. Wilcox R.A., Flies D.B., Zhu G., Johnson A.J., Tamada K., Chapoval A.I., Strome S.E., Pease L.R., Chen L. Provision of antigen and CD137 signaling breaks immunological ignorance, Promoting regression of poorly immunogenic tumors. J. Clin. Invest. 2002, 109:651-659.
34. Diehl L., van Mierlo G.J., den Boer A.T., van der Voort E., Fransen M., van Bostelen L., Krimpenfort P., Melief C.J., Mittler R., Toes R.E., Offringa R. In vivo triggering through 4-1BB enables Th-independent priming of CTL in the presence of an intact CD28 costimulatory pathway. J. Immunol. 2002, 168:3755-3762.
35. Cheuk A.T., Mufti G.J., Guinn B.A. Role of 4-1BB:4-1BB ligand in cancer immunotherapy. Cancer Gene Ther. 2004, 11:215-226.
36. Futagawa T., Akiba H., Kodama T., Takeda K., Hosoda Y., Yagita H., Okumura K. Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells. Int. Immunol. 2002, 14:275-286.
37. Baird S.D., Turcotte M., Korneluk R.G., Holcik M. Searching for IRES. RNA 2006, 12:1755-1785.
38. Habib-Agahi M., Phan T.T., Searle P.F. Co-stimulation with 4-1BB ligand allows extended T-cell proliferation, synergizes with CD80/CD86 and can reactivate anergic T cells. Int. Immunol. 2007, 19:1383-1394.
39. Sun Y., Chen J.H., Fu Y. Immunotherapy with agonistic anti-CD137: two sides of a coin. Cell Mol. Immunol. 2004, 1:31-36.